ALNYLAM PHARMA (DUL MU) stock market data APIs
€388.1018
-3.2(-0.8%)
as of September 17, 2025
Try our APIs with
free plan!
ALNYLAM PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for DUL.MU.
Prev. Close
388.1018
Open
384.9037
High
388.1018
Low
384.9037
52 wk Range
192.15-408.5
Market Cap
18 390 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALNYLAM PHARMA data using free add-ons & libraries
Get ALNYLAM PHARMA Fundamental Data
ALNYLAM PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALNYLAM PHARMA News
New
Will Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative?
In early September 2025, Alnylam Pharmaceuticals announced and completed a US$575 million convertible zero coupon senior unsecured note offering due September 2028 and presented extensive long-term da...
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam Pharmaceuticals (ALNY) shares rallied 6% in the last trading session to close at $482.13. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
CAMBRIDGE, Mass., September 10, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously an...
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
CAMBRIDGE, Mass., September 08, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
